Validation of Continuous Monitoring of Vital Signs in Children With a Connected Patch
NCT ID: NCT04627766
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
48 participants
INTERVENTIONAL
2025-02-02
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this study is to assess the accuracy of a connected thoracic patch (VT-Patch) for the continuous monitoring of vital signs in PICU patients.
This monitoring device will be used to monitor children in PICU for 8 hours and results will be compared to the standard of care in the unit which is the Philips monitoring system.
The investigators will assess the device's accuracy for the monitoring of 4 vital signs (SpO2, heart rate, respiratory rate and temperature) and perform exploratory assessment of three additional parameters (EKG, blood pressure and movement capture). The skin colour of each participant will be categorized based on Fitzpatrick scale and non-invasive spectroscopic method.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients readmission to PICU is a major point of concern for physician because, although being a rare event, it has been strongly associated to more morbidity and death. Patients monitoring once they have left the PICU is drastically modified and small connected devices could be an option to early identify patients at risk of PICU readmission. Such devices have been manufactured for the monitoring of adults but they do not exist for children.
Besides, studies have recently shown that devices that use optical sensors may be less accurate in individuals with dark skin pigmentation since dark skin tones impose a limitation on optical biometric sensing. The wearable and medical device industry has not sufficiently addressed this issue yet. This is one of the main challenges that need to be addressed in this area to make sure the connected devices using this technology will work with all different skin colours including very dark skin.
Main objective:
Assess the accuracy of VT-Patch to measure oxygen saturation (SpO2) in children with diverse skin colour.
Secondary objectives:
Assess the accuracy of VT-Patch monitoring for 3 additional physiologic parameters (heart rate (HR), respiratory rate (RR) and temperature). Exploratory assessment of blood pressure (BP) monitoring, ECG signal and movement capture. The effect of the skin colour on the vital signs measurements will be investigated as well.
Design:
Prospective validation study of VT-Patch device for the monitoring of 4 physiologic parameters and exploratory assessment of three additional parameters.
Methods:
The study will be performed in two successive phases:
* Run-in phase: testing the device on 5 children to assess the feasibility of the protocol.
* Main study: validation phase of the device on 2 children per age group per skin phototype (based on Monk scale) to assess its accuracy. The patients of the run-in phase will be included in the main study if no modification of the protocol is required.
4 physiologic parameters (HR, SpO2, RR, temperature and BP) and ECG will be prospectively recorded during 8 hours with VT-Patch and the regular monitoring system implemented in the unit High-resolution database that will be the Gold standard for evaluation.
Participating center: 1 center (St. Justine's Hospital).
Perspectives: This validation step of the collected data is necessary to validate that VT-Patch is suitable for pediatric patient monitoring of all skin colors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Monitored children
PICU Children that will be monitored with the device
Monitoring with VT-Patch (Connected device manufactured by VitalTracer)
Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Monitoring with VT-Patch (Connected device manufactured by VitalTracer)
Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PICU monitoring for the next 24 hours
Exclusion Criteria
* Thoracic skin lesion that contraindicates the VT-Patch
* No parental consent
* Intermittent presence of one study observer in the patient room is considered inappropriate by the physician or the nurse in charge because of the child's medical condition
0 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Justine's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Philippe Jouvet
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe Jouvet, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
St. Justine's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Sainte Justin Hospital
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-3157
Identifier Type: -
Identifier Source: org_study_id